Literature DB >> 2876509

Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance.

G Williams, H Fuessl, M Kraenzlin, S R Bloom.   

Abstract

SMS 201-995 (5-100 micrograms) injected subcutaneously in normal and type-2 diabetic subjects 30 min before a test meal caused dose-related suppression of plasma concentrations of insulin, glucagon, and several regulatory gut peptide hormones (gastrin, gastric inhibitory peptide, pancreatic polypeptide, secretin, neurotensin, and motilin). Effective hormone suppression was achieved even at the lowest dose of 5 micrograms. In the normal subjects SMS caused postprandial hyperglycaemia, but there was no overall deterioration in glucose tolerance in the type-2 diabetic patients. This suggests that counterregulatory hormones play an important part in the metabolic disturbance of type-2 diabetes.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2876509     DOI： 10.3109/00365528609087434

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN： 0085-5928


  9 in total

1.  Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.

Authors:  A J Scheen; J Gillet; J Rosenthaler; J Guiot; P Henrivaux; B Jandrain; P J Lefèbvre
Journal:  Diabetologia       Date:  1989-11       Impact factor: 10.122

Review 2.  Pathophysiology, diagnosis and management of postoperative dumping syndrome.

Authors:  Jan Tack; Joris Arts; Philip Caenepeel; Dominiek De Wulf; Raf Bisschops
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-01       Impact factor: 46.802

3.  Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995.

Authors:  W P Hopman; R G Wolberink; C B Lamers; J H Van Tongeren
Journal:  Ann Surg       Date:  1988-02       Impact factor: 12.969

Review 4.  The significance of gastrin in the pathogenesis and therapy of peptic ulcer disease.

Authors:  C B Lamers
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Effects of octreotide on manometric variables in patients with neuropathic abnormalities of the small bowel.

Authors:  G Bassotti; U Germani; C Calcara; F Spinozzi; P Roselli; A Morelli
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

Review 6.  Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.

Authors:  A G Harris
Journal:  Gut       Date:  1994       Impact factor: 23.059

7.  Effect of synthetic prostaglandin E2 analog enprostil on omeprazole-induced hypergastrinemia and hyperpepsinogenemia.

Authors:  J L Meijer; L F Crobach; J B Jansen; C B Lamers
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

Review 8.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

9.  Driver versus navigator causation in biology: the case of insulin and fasting glucose.

Authors:  Manawa Diwekar-Joshi; Milind Watve
Journal:  PeerJ       Date:  2020-12-11       Impact factor: 2.984
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.